Tissue Repair Limited to enter a phase 3 program in venous leg ulcers. If the trials for its lead drug candidate TR-987® are successful the Company will be the first drug approved for venous leg ulcers in over 25 years, a large and growing market with a similar cost to treat of some cancers. The company announced that its USA patent application 17/845,098, with claims for use of the Company's Active Pharmaceutical Ingredient (API) Glucoprime® for topically applied methods of treating any skin condition, has been allowed by the US Patent and Trademark Office (USPTO).

Glucoprime® is the API used in formulating the Company's first drug candidate TR987® for treatment of venous leg ulcers and it TR Pro+ TM a product for post-operative cosmeceutical application in a number of dermatological and related treatments. This new patent approval follows the very recent approval of TRs first patent in April 2022, with claims on the method of manufacturing of Glucoprime® (US Patent No. 11,384,160 on 12 July 2022).

There are no known alternative processes from which to produce the Company's proprietary biological polysaccharide molecule. The now allowed portfolio of granted patent applications represent a core component of the Company's IP and protects both the Company's process for the manufacture of its API and its exclusive rights over its intended uses of its unique biological proprietary polysaccharide molecule across a large number of skin conditions in very large markets.